



COMPANY OVERVIEW

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

RECENT NEWS

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Aug 13 2025, 8:00 AM EDT

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 30 2025, 9:00 AM EDT

STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	14.59m
Last Price	\$9.46
52-Week Range	\$2.20 - \$13.93

10/09/2025 08:00 PM EDT

INVESTOR RELATIONS

JTC Team, LLC.
Jenene Thomas
T: 908-824-0775
xbio@jtcir.com

MANAGEMENT TEAM

James F. Parslow

Interim Chief Executive Officer and Chief Financial Officer

Scott N. Cullison

Business Development

Reid P. Bissonnette, Ph.D.

Translational Research and Development

XENETIC BIOSCIENCES, INC.

945 Concord Street
Framingham, MA 01701
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.